# US 2024/0189391 A1 · Compositions and methods for treating spinal muscular atrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189391 A1
- Document ID: US20240189391A1
- Status: Published application
- Kind: A1
- Application number: 18/509,798
- Filed: 2023-11-15
- Published: 2024-06-13
- Earliest claimed: 2017-04-03
- Assignees: Acceleron Pharma Inc.
- Applicants: Acceleron Pharma Inc.
- Inventors: Ravindra Kumar; Naga Venkata Sai Rajasekhar Suragani; Jia Li
- Web page: https://patentgrep.com/patent/US20240189391A1

## CPC

- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 38/18: Growth factors; Growth regulators
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 14/495: Transforming growth factor [TGF]
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/179: {for growth factors; for growth regulators}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C12N 2310/11: Antisense
- C12N 2320/31: Combination therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In certain aspects, the disclosure provides compositions and methods for treating spinal muscular atrophy. For example, in some embodiments, the disclosure provides ALK4:ActRIIB antagonists that may be used to treat spinal muscular atrophy, particularly treating one or more complications of spinal muscular atrophy including, for example, increasing muscle mass muscle strength, and bone mineral density.

## Claims

### Claim 1

A method of treating spinal muscular atrophy (SMA) in a patient, comprising administering to a patient in need thereof an effective amount of an ALK4:ActRIIB antagonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method prevents or reduces the severity of one or more complications of SMA selected from: areflexia, particularly in the extremities; overall muscle weakness; respiratory complications; respiratory failure; respiratory insufficiency; poor muscle tone; limpness or a tendency to flop; difficulty in achieving developmental milestones; difficulty sitting, standing, and/walking; loss of strength of respiratory muscles, often resulting in weak cough, weak cry, accumulation of secretions in lungs or throat, and/or respiratory distress; fasciculation of the tongue; bone loss (e.g., low bone mineral density) and/or weakness; difficulty sucking or swallowing, often resulting in poor feeding.

### Claim 3

The method of any preceding claim, wherein patient has SMA3.

### Claim 4

The method of any preceding claim, wherein the method increases bone mineral density in the patient.

### Claim 5

The method of any preceding claim, wherein the method increases muscle mass in the patient.

### Claim 6

The method of any preceding claim, wherein the method increases muscle strength in the patient.

### Claim 7

The method of any preceding claim, wherein the method results in improvement in motor milestones according to Section 2 of the Hammersmith Infant Neurologic Exam (HINE).

### Claim 8 (depends on 7)

The method of claim 7, wherein the method results in at least a 2-point increase in ability to kick in accordance with Section 2 of HINE.

### Claim 9 (depends on 7, 8)

The method of claim 7 or 8, wherein the method results in at least a 1-point increase in the motor milestones of head control, rolling, sitting, crawling, standing, voluntary grasp, or walking in accordance with section 2 of HINE.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the method results in improvement in motor function according to the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend).

### Claim 11 (depends on 10)

The method of claim 10, wherein the method results in at least a 4-point increase in motor function in accordance with CHOP Intend.

### Claim 12

The method of any of the preceding claims, wherein the method further comprises administration of an additional active agent or supportive therapy for treating SMA.

### Claim 13 (depends on 12)

The method of claim 12, wherein the additional active agent is nusinersen.

### Claim 14 (depends on 12)

The method of claim 12, wherein the additional active agent or supportive therapy is selected from: SMN1 gene replacement (e.g., AVXS-101 gene therapy), SMN2 alternative splicing modulation (e.g., branaplam, RG7916, RG3039, PTK-SMA1, RG7800, sodium orthovanadate, and aclarubicin), SMN2 gene activation (e.g., salbutamol, butyrates, valproic acid, hydroxycarbamide), histone deacetylase inhibitors, benzamide M344, hydroxamic acids (e.g., CBHA, SBHA, entinostat, panobinostat, trichostatin A, and vorinostat), prolactin, natural polyphenol compounds (e.g., resveratrol and curcumin), p38 pathway activators (e.g., celecoxib), SMN stabilization (e.g., aminoglycosides and indoprofen), neuroprotection (e.g., olesoxime, thyrotropin-releasing hormone, riluzole, beta-lactam antibiotics (e.g., ceftriaxone), and muscle restoration (e.g., CK-2127107).

### Claim 15

The method of any preceding claim, wherein the ALK4:ActRIIB antagonists is a recombinant ALK4:ActRIIB heteromultimer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the ALK4:ActRIIB heteromultimer comprises at least one ALK4 polypeptide comprising an amino acid sequence selected from:
a. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a polypeptide that
i. begins at any one of amino acids of 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 SEQ ID NO: 9, and
ii. ends at any one of amino acids 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, or 126 of SEQ ID NO: 9;
b. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 34-101 of SEQ ID NO: 9;
c. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 10;
d. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a polypeptide that
i. begins at any one of amino acids of 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 SEQ ID NO: 19, and
ii. ends at any one of amino acids 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, or 126 of SEQ ID NO: 19;
e. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 34-101 of SEQ ID NO: 19; and
f. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the ALK4:ActRIIB heteromultimer comprises at least one ActRIIB polypeptide comprising an amino acid sequence selected from:
a. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a polypeptide that:
i. begins at any one of amino acids of 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 SEQ ID NO: 1, and
ii. ends at any one of amino acids 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, or 134 of SEQ ID NO: 1;
b. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 29-109 of SEQ ID NO: 1;
c. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 25-131 of SEQ ID NO: 1;
d. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2;
e. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 3;
f. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 5; and
g. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 6.

### Claim 18 (depends on 17)

The method of claim 17, wherein the ActRIIB polypeptide domain does not comprise an acidic amino acid at the position corresponding to L79 of SEQ ID NO: 1.

### Claim 19 (depends on 15, 16, 17, 18)

The method of any one of claims 15-18, wherein the ALK4 polypeptide and/or ActRIIB polypeptide is an immunoglobulin Fc fusion protein.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The method of any one of claims 15-19, wherein the ALK4-Fc fusion protein further comprises a linker domain positioned between the ALK4 domain and the Fc domain and/or the ActRIIB fusion protein further comprises a linker domain positioned between the ActRIIB domain and the Fc domain.

### Claim 21 (depends on 20)

The method of claim 20, wherein the linker domain is selected from: TGGG (SEQ ID NO: 17), TGGGG (SEQ ID NO: 15), SGGGG (SEQ ID NO: 16), GGGGS (SEQ ID NO: 58), GGG (SEQ ID NO: 13), GGGG (SEQ ID NO: 14), SGGG (SEQ ID NO: 18), and GGGGS (SEQ ID NO: 58).

### Claim 22 (depends on 19)

The method of claim 19, wherein the ALK4-Fc fusion protein comprises an amino acid sequence selected from:
a. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 44;
b. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 48; and
c. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 76.

### Claim 23 (depends on 19, 22)

The method of claim 19 or 22, wherein the ActRIIB-Fc fusion protein comprises an amino acid sequence selected from:
a. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41;
b. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 46;
c. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 72; and
d. an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 80.

### Claim 24 (depends on 23)

The method of claim 23, wherein the ActRIIB domain of the ActRIIB-Fc fusion protein does not comprise an acidic amino acid at the position corresponding to L79 of SEQ ID NO: 1.

### Claim 25 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 15-24, wherein the ALK4 polypeptide and/or ActRIIB polypeptide comprise one or more mutations that promote heteromultimer formation and/or inhibit homomultimer formation.

### Claim 26 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 15-25, wherein the ALK4:ActRIIB heteromultimer is a heterodimer.

### Claim 27 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 15-26, wherein the ALK4 polypeptide, ALK4-Fc fusion protein, ActRIIB polypeptide, and/or ActRIIB-Fc fusion protein comprises one or more modified amino acid residues selected from: a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, and an amino acid conjugated to a lipid moiety.

### Claim 28 (depends on 27)

The method of claim 27, wherein the ALK4 polypeptide, ALK4-Fc fusion protein, ActRIIB polypeptide, and/or ActRIIB-Fc fusion protein is glycosylated and has a glycosylation pattern obtainable from a Chinese hamster ovary (CHO) cell line.

### Claim 29 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 15-28, wherein the heteromultimer binds to one or more ligands selected from: activin A, activin B, GDF8, GDF11, BMP6, BMP10, and GDF3.

### Claim 30 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 15-29, wherein the heteromultimer does not substantially bind to BMP9.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the ALK4:ActRIIB antagonist is an antibody or combination of antibodies that binds to one or more of activin A, activin B, GDF11, GDF8, GDF11, BMP6, BMP10, and GDF3.

### Claim 32 (depends on 31)

The method of claim 31, wherein the ALK4:ActRIIB antagonist is an antibody or combination of antibodies that binds one or more of activin A, activin B, GDF11, and GDF8.
